- Telomir Pharmaceuticals, a pre-clinical-stage pharmaceutical company, on Thursday announced the pricing of its initial public offering of 1,000,000 shares of its common stock at a public offering price of $7.00 per share.
- Telomir has granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of common stock at the initial public offering price.
- The shares are expected to begin trading on Nasdaq on February 9, 2024 under the ticker symbol “TELO.”
- The gross proceeds to Telomir from the initial public offering are expected to be $7 million.
- The initial public offering is expected to close on February 13.
- Source: Press Release
